Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.85
-0.03 (-0.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
Immatics Revenue
Immatics had revenue of 50.56M EUR in the quarter ending September 30, 2024, with 753.17% growth. This brings the company's revenue in the last twelve months to 115.50M, up 52.53% year-over-year. In the year 2023, Immatics had annual revenue of 54.00M, down -68.76%.
Revenue (ttm)
115.50M EUR
Revenue Growth
+52.53%
P/S Ratio
5.18
Revenue / Employee
215,895 EUR
Employees
535
Market Cap
817.59M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
Dec 31, 2020 | 31.25M | 12.80M | 69.40% |
Dec 31, 2019 | 18.45M | 14.68M | 389.36% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 5.59B |
Healthcare Services Group | 1.70B |
Castle Biosciences | 311.88M |
Paragon 28 | 245.00M |
Cytek Biosciences | 201.21M |
Avid Bioservices | 150.45M |
Prothena Corporation | 133.35M |
AbCellera Biologics | 32.96M |
IMTX News
- 4 weeks ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 6 weeks ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire
- 2 months ago - Immatics: A Promising TCR Pipeline - Seeking Alpha
- 2 months ago - Immatics Announces Pricing of $150 Million Public Offering - GlobeNewsWire
- 2 months ago - Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday? - Benzinga
- 2 months ago - Immatics Announces Proposed $150 Million Public Offering - GlobeNewsWire
- 2 months ago - Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial - GlobeNewsWire
- 2 months ago - Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - GlobeNewsWire